Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.85B |
| 2 |
Tesla
TSLA
|
+$1.78B |
| 3 |
Apple
AAPL
|
+$1.57B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.49B |
| 5 |
Mastercard
MA
|
+$1.09B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.3B |
| 2 |
Phillips 66
PSX
|
+$650M |
| 3 |
iShares China Large-Cap ETF
FXI
|
+$475M |
| 4 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$432M |
| 5 |
NRG Energy
NRG
|
+$387M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.59% |
| 2 | Financials | 9.21% |
| 3 | Consumer Discretionary | 7.33% |
| 4 | Healthcare | 5.59% |
| 5 | Communication Services | 5.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4301
iShares US Medical Devices ETF
IHI
$3.13B
| $96.4K | ﹤0.01% |
1,602
-12,694
| -89% | -$788K |
|
4302
Caribou Biosciences
CRBU
$145M
| $95.3K | ﹤0.01% |
104,408
-41,009
| -28% | -$53.3K |
|
4303
Zentalis Pharmaceuticals
ZNTL
$337M
| $94.8K | ﹤0.01% |
59,616
-57,779
| -49% | -$125K |
|
4304
Upland Software
UPLD
$12.8M
| $94K | ﹤0.01% |
3,286
| – | – |
|
|
KZIA
4305
Kazia Therapeutics
KZIA
$144M
| $93.9K | ﹤0.01% |
24,000
| – | – |
|
4306
AbCellera Biologics
ABCL
$1.74B
| $93.4K | ﹤0.01% |
41,895
+3,544
| +9% | +$10.2K |
|
4307
Sight Sciences
SGHT
$286M
| $92.7K | ﹤0.01% |
38,645
-17,649
| -31% | -$49.7K |
|
4308
Innovator US Equity Buffer ETF September
BSEP
$217M
| $92.1K | ﹤0.01% |
2,205
+2,159
| +4,693% | +$93K |
|
|
NB
4309
NioCorp Developments
NB
$619M
| $92.1K | ﹤0.01% |
46,749
| – | – |
|
4310
Structure Therapeutics
GPCR
$3.41B
| $92K | ﹤0.01% |
5,312
-110,359
| -95% | -$2.7M |
|
4311
Polestar Automotive Holding UK
PSNY
$2.09B
| $91.7K | ﹤0.01% |
2,911
-75
| -3% | -$2.48K |
|
|
SERV
4312
Serve Robotics
SERV
$407M
| $91.4K | ﹤0.01% |
+15,892
| New | +$208K |
|
4313
iShares Cybersecurity and Tech ETF
IHAK
$1B
| $91.2K | ﹤0.01% |
1,941
| – | – |
|
4314
State Street SPDR Portfolio Intermediate Term Corporate Bond ETF
SPIB
$11.5B
| $90.9K | ﹤0.01% |
2,736
| – | – |
|
4315
Inseego
INSG
$114M
| $90.6K | ﹤0.01% |
11,087
-6,911
| -38% | -$75.6K |
|
|
DCBO
4316
Docebo
DCBO
$525M
| $90.4K | ﹤0.01% |
3,150
-29
| -0.9% | -$1.1K |
|
4317
Wipro
WIT
$19.6B
| $90.2K | ﹤0.01% |
29,466
-100,856
| -77% | -$344K |
|
4318
Caesarstone
CSTE
$72.3M
| $89.6K | ﹤0.01% |
36,857
-10,220
| -22% | -$38.3K |
|
|
NYAX
4319
Nayax
NYAX
$2.55B
| $89.4K | ﹤0.01% |
2,641
+360
| +16% | +$13K |
|
4320
Fossil Group
FOSL
$293M
| $89.2K | ﹤0.01% |
77,597
| – | – |
|
|
SPYM
4321
State Street SPDR Portfolio S&P 500 ETF
SPYM
$161B
| $88.8K | ﹤0.01% |
1,350
| – | – |
|
4322
Geospace Technologies
GEOS
$94.6M
| $88.5K | ﹤0.01% |
12,280
-6,038
| -33% | -$51.8K |
|
4323
Vanguard Real Estate ETF
VNQ
$39.2B
| $88.3K | ﹤0.01% |
975
+19
| +2% | +$1.72K |
|
4324
Lineage Cell Therapeutics
LCTX
$269M
| $88.1K | ﹤0.01% |
195,045
-39,024
| -17% | -$22.9K |
|
|
MBX
4325
MBX Biosciences
MBX
$3.14B
| $87.2K | ﹤0.01% |
11,818
-5,615
| -32% | -$59.4K |
|
Similar funds
Barclays's Q1 2025 Portfolio in Review
As of Q1 2025, Barclays held 5,710 positions worth $353B, down 1.2% from $357B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Barclays deployed $16.5B of net new capital in Q1 2025, opening 439 new positions and adding to 1,449 existing holdings. Its largest new stake was JPMorgan BetaBuilders USD High Yield Corporate Bond ETF: 318,453 shares worth $14.7M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Honeywell, an estimated $1.3B trimmed.
- Barclays's largest Q1 2025 buy was JPMorgan BetaBuilders USD High Yield Corporate Bond ETF: 318,453 shares worth $14.7M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $3.85B increase.
- Barclays's biggest Q1 2025 reduction was Honeywell, cutting an estimated $1.3B.
- Barclays fully exited Smartsheet Inc. in Q1 2025, selling an estimated $45.7M.
- Barclays's ten largest holdings make up 37% of its $353B portfolio in Q1 2025.
- Barclays opened 439 new positions and closed 470 in Q1 2025.
- Barclays's portfolio value fell 1.2% quarter-over-quarter to $353B.
Based on Barclays's 13F filing for Q1 2025, filed 15 May 2025.